In vivo evaluation for rhGM-CSF wound-healing efficacy in topical vehicles.
The wound-healing efficacy of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) was studied in a mouse model. Full-thickness wounds were treated with liquid crystalline, emulsion, and niosome vehicles alone and with rhGM-CSF. The control group was non-medicated. Observation of the vehicle groups with and without the rhGM-CSF displayed better healing profiles than the control group. The vehicles were also evaluated among themselves and it was noted that emulsion base and niosome base groups gave significantly better healing profiles and histological results than the liquid crystalline base group. Among the rhGM-CSF containing groups, emulsion formulation displayed a stronger wound-healing effectiveness compared to the other formulations. In vitro release characteristics of the recombinant protein from the three vehicle formulations were demonstrated with diffusion cells. Histological and immunohistochemical evaluation was performed on biopsies taken on the last day of the experiment.
Memişoğlu
E
E
Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, Turkey.
Oner
F
F
Ayhan
A
A
Başaran
I
I
Hincal
A A
AA
D000818:Animals; D004655:Emulsions; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage* / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D014677:Pharmaceutical Vehicles; D011994:Recombinant Proteins; D012867:Skin / Q000293:injuries / Q000473:pathology; D013056:Spectrophotometry, Ultraviolet; D014945:Wound Healing / Q000187:drug effects*; D014947:Wounds and Injuries / Q000473:pathology
D004655:Emulsions; D014677:Pharmaceutical Vehicles; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor